Abstract：
Prostate cancer is a malignant epithelial tumor of the prostate gland and is the most common malignant tumor of the male genitourinary system. Pharmacological therapies, including chemotherapy and androgen deprivation therapy, play a key role in the treatment of prostate cancer. However, drug resistance and side effects limit the use of these drugs and so there is a need for new drug therapies for prostate cancer patients. Flavonoids, with their wide range of sources and diverse biological activities, have attracted much attention in the field of anti-tumor drug screening. In 2016, at least 58 flavonoids were reported to have anti-prostate cancer activity. In recent years, six additional flavonoid compounds have been found to have anti-prostate cancer potential. In this review, we have collected a large amount of evidence on the anti-prostate cancer effects of these six flavonoids, including a large number of cellular experiments and a small number of preclinical animal experiments. In addition, we predicted their drug-forming properties using Schrödinger\'s QikProp software and ADMETlab due to the lack of in vivo pharmacokinetic data for the six compounds. In conclusion, this review has fully confirmed the anti-prostate cancer effects of these six flavonoids, summarized their mechanisms of action and predicted their druggability. It provides a reference for the further development of these compounds into anti-prostate cancer drugs.
摘要：
前列腺癌是前列腺的恶性上皮肿瘤，是男性泌尿生殖系统最常见的恶性肿瘤。药物疗法,包括化疗和雄激素剥夺治疗，在前列腺癌的治疗中起关键作用。然而,耐药性和副作用限制了这些药物的使用，因此需要针对前列腺癌患者的新药治疗。黄酮类化合物,来源广泛，生物活动多样，在抗肿瘤药物筛选领域备受关注。2016年，据报道至少有58种类黄酮具有抗前列腺癌活性。近年来,已发现另外6种类黄酮化合物具有抗前列腺癌的潜力.在这次审查中,我们收集了大量关于这六种黄酮类化合物抗前列腺癌作用的证据，包括大量的细胞实验和少量的临床前动物实验。此外,由于缺乏6种化合物的体内药代动力学数据，我们使用Schrödinger的QikProp软件和ADMETlab预测了它们的药物形成特性。总之,这篇综述已经充分证实了这六种黄酮类化合物的抗前列腺癌作用，总结了它们的作用机制，并预测了它们的可药用性。为这些化合物进一步发展为抗前列腺癌药物提供参考。
